Enanta Pharmaceuticals Inc. (ENTA) Shares Down 2.2%
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)’s share price traded down 2.2% during mid-day trading on Thursday . The company traded as low as $23.10 and last traded at $23.20, with a volume of 102,744 shares traded. The stock had previously closed at $23.73.
ENTA has been the subject of several recent analyst reports. Vetr cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 target price for the company. in a research report on Monday, April 25th. JMP Securities cut Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 28th. Finally, Zacks Investment Research cut Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 12th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $28.58.
The stock’s 50 day moving average price is $23.51 and its 200-day moving average price is $27.21. The stock has a market capitalization of $441.89 million and a PE ratio of 13.70.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 9th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.10 by $0.19. The business had revenue of $13 million for the quarter, compared to the consensus estimate of $16.80 million. During the same period last year, the firm earned $1.49 EPS. The business’s revenue was down 77.4% on a year-over-year basis. Equities analysts forecast that Enanta Pharmaceuticals Inc. will post $1.00 EPS for the current year.
Several hedge funds have modified their holdings of the stock. Matarin Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at approximately $4,644,000. Schroder Investment Management Group boosted its stake in shares of Enanta Pharmaceuticals by 91.8% in the fourth quarter. Schroder Investment Management Group now owns 439,303 shares of the company’s stock valued at $14,506,000 after buying an additional 210,303 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Enanta Pharmaceuticals by 142.4% in the fourth quarter. Wells Fargo & Company MN now owns 89,541 shares of the company’s stock valued at $2,956,000 after buying an additional 52,600 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Enanta Pharmaceuticals by 114.7% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 32,851 shares of the company’s stock valued at $1,085,000 after buying an additional 17,551 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its stake in shares of Enanta Pharmaceuticals by 44.3% in the fourth quarter. GSA Capital Partners LLP now owns 80,322 shares of the company’s stock valued at $2,652,000 after buying an additional 24,670 shares during the last quarter.
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.